Related Experiment Videos

Cancer in the elderly: why so badly treated?

I S Fentiman¹, U Tirelli, S Monfardini

¹ICRF Clinical Oncology Unit, Guy's Hospital, London, UK.

Lancet (London, England)

|April 28, 1990

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.

ESMO open·2021

Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial.

Expert review of clinical pharmacology·2021

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

BioMed research international·2014

A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).

Gynecologic oncology·2012

Patterns of metastasis in women with metachronous contralateral breast cancer.

British journal of cancer·2012

Serum cotinine and prognosis in breast cancer.

Breast cancer research and treatment·2012

See all related articles